Personnel expenses in the first three months of 2026 increased $5.3 million primarily driven by increased headcount and higher salaries from annual merit increases and higher fringe benefit costs.

filing / May 5, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.

filing / May 5, 2026 / receipt

The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services.

filing / May 5, 2026 / receipt

Furthermore, our business strategy incorporates potential international expansion as we seek to obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the United States.

filing / May 5, 2026 / receipt

Any of these factors could harm our future international expansion and operations and, consequently, our results of operations.

filing / May 5, 2026 / receipt

John Crowley has served as our Chief Financial Officer since June 2024. He has over 20 years of global finance and operational experience in the life sciences industry.

filing / Apr 29, 2026 / receipt

The Company may satisfy SEC rules regarding delivery of proxy materials, including this proxy statement and our Annual Report, by delivering a single set of proxy materials to an address shared by two or more Company shareholders or ADS holders, a practice known as “householding.” This delivery method can result in meaningful cost savings for the Company.

filing / Apr 29, 2026 / receipt

This process, which is commonly referred to as “householding,” potentially means extra convenience for shareholders and cost savings for companies.

filing / Apr 29, 2026 / receipt